Meganeuro ampoules 5 ml

It has antihypoxic, membrane-protective, nootropic, anticonvulsant, anxiolytic effects, and increases the body's resistance to stress. The drug increases the body's resistance to the effects of major damaging factors, to oxygen-dependent pathological conditions (shock, hypoxia and ischemia, cerebrovascular accident, intoxication with alcohol and antipsychotic drugs (neuroleptics)).

1 ml of solution contains:

• Ethylmethylhydroxypyridine succinate - 50 mg;
• Excipients: water for injection 5 ml.

• acute cerebrovascular accidents;
• traumatic brain injury, consequences of traumatic brain injury;
• encephalopathy;
• autonomic dystonia syndrome;
• mild cognitive disorders of atherosclerotic origin;
• anxiety disorders in neurotic and neurosis-like conditions;
• acute myocardial infarction (from the first day) as part of complex therapy;
• primary open-angle glaucoma of various stages, as part of complex therapy;
• relief of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;
• acute intoxication with antipsychotic drugs;
• acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis) as part of complex therapy.

Method of administration and dose: IM or IV (stream or drip). When administered by infusion, the drug should be diluted in 0.9% sodium chloride solution. Meganeuro is injected slowly over 5-7 minutes, and drip-wise at a rate of 40-60 drops per minute. The maximum daily dose should not exceed 1200 mg. In case of acute cerebrovascular accidents, Meganeuro is used in the first 10–14 days – 200–500 mg intravenously 2–4 times a day, then 200–250 mg intramuscularly 2–3 times a day for 2 weeks.

For traumatic brain injury and the consequences of traumatic brain injury, Meganeuro is used for 10 - 15 days by intravenous drips of 200 - 500 mg 2 - 4 times a day.
For dyscirculatory encephalopathy in the decompensation phase, Meganeuro should be prescribed intravenously in a stream or drip at a dose of 200–500 mg 1–2 times a day for 14 days.
Then IM 100 – 250 mg/day over the next 2 weeks.
For a course of prophylaxis of discirculatory encephalopathy, the drug is administered intramuscularly at a dose of 200–250 mg 2 times a day for 10–14 days. 

For mild cognitive impairment in elderly patients and anxiety disorders, the drug is used intramuscularly at a daily dose of 100–300 mg/day for 14–30 days.